Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.

Park S, Lee J, Lee SY, Bae JW, Hwang KK, Kim DW, Cho MC, Kim SM.

Korean Circ J. 2013 Aug;43(8):557-60. doi: 10.4070/kcj.2013.43.8.557. Epub 2013 Aug 31.

2.

Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.

Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.

Circulation. 2010 Dec 21;122(25):2709-17. doi: 10.1161/CIRCULATIONAHA.110.002741. Epub 2010 Nov 15.

3.

Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.

J Am Coll Cardiol. 2010 Aug 3;56(6):463-9. doi: 10.1016/j.jacc.2009.08.093.

4.

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.

Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.

5.
6.

Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.

Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Gaudreault V, Proulx G, Barbeau G, Déry JP, Gleeton O, Manh-Nguyen C, Noël B, Roy L, Costerousse O, De Larochellière R; EArly Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASY-MI) Study Investigators..

Am J Cardiol. 2010 Jun 1;105(11):1520-7. doi: 10.1016/j.amjcard.2010.01.006. Epub 2010 Apr 14.

PMID:
20494655
7.

Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.

Pride YB, Mohanavelu S, Zorkun C, Kunadian V, Giugliano RP, Newby LK, Braunwald E, Califf RM, Harrington RA, Gibson CM; EARLY ACS Investigators..

JACC Cardiovasc Interv. 2012 Sep;5(9):927-35. doi: 10.1016/j.jcin.2012.05.007.

8.

Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention.

Chan W, Stub D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan AL, New G, Black A, Shaw JA, Reid CM, Dart AM, Duffy SJ; Melbourne Interventional Group Investigators..

Am J Cardiol. 2012 Feb 15;109(4):478-85. doi: 10.1016/j.amjcard.2011.09.037. Epub 2011 Dec 15.

PMID:
22176999
9.

Percutaneous cardiopulmonary support in refractory no-reflow with cardiogenic shock after coronary stenting in acute myocardial infarction.

Son JW, Kim JS, Lee JM, Hong SJ, Jung MK, Kim DH, Kim JS, Choi D, Jang Y.

Yonsei Med J. 2010 Jul;51(4):599-601. doi: 10.3349/ymj.2010.51.4.599.

10.

Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).

Singh HS, Dangas GD, Guagliumi G, Yu J, Witzenbichler B, Kornowski R, Grines C, Gersh B, Dudek D, Mehran R, Stone GW.

Am J Cardiol. 2012 Oct 1;110(7):940-7. doi: 10.1016/j.amjcard.2012.05.026. Epub 2012 Jun 28.

PMID:
22748356
11.

Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice.

Heer T, Zeymer U, Juenger C, Gitt AK, Wienbergen H, Zahn R, Gottwik M, Senges J; Acute Coronary Syndromes Registry Investigators..

Heart. 2006 Oct;92(10):1484-9. Epub 2006 Apr 10.

12.

Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.

Mehilli J, Kastrati A, Schulz S, Früngel S, Nekolla SG, Moshage W, Dotzer F, Huber K, Pache J, Dirschinger J, Seyfarth M, Martinoff S, Schwaiger M, Schömig A; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators..

Circulation. 2009 Apr 14;119(14):1933-40. doi: 10.1161/CIRCULATIONAHA.108.818617. Epub 2009 Mar 30.

13.

Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Celık T, Balta S, Demır M, Yıldırım AO, Kaya MG, Ozturk C, Demırkol S, Unlu M, Kılıc S, Aydın İ, Iyısoy A.

Cardiol J. 2016;23(1):84-92. doi: 10.5603/CJ.a2015.0070. Epub 2015 Oct 27.

14.

Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.

Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.

Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.

16.

Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.

Uyarel H, Uzunlar B, Unal Dayi S, Tartan Z, Samur H, Kasikcioglu H, Akgul O, Simsek D, Erdem I, Okmen E, Cam N.

Cardiology. 2006;105(3):168-75. Epub 2006 Feb 13.

PMID:
16479104
18.
19.

Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.

Bajaj RR, Mohammad A, Hong T, Irfan A, Sharieff W, Bagnall A, Christie JA, Kutryk MJ, Chisholm RJ, Cheema AN.

J Invasive Cardiol. 2010 Aug;22(8):347-52.

20.

Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention.

Huang R, Sacks J, Thai H, Goldman S, Morrison DA, Barbiere C, Ohm J.

Catheter Cardiovasc Interv. 2005 May;65(1):25-33.

PMID:
15800889

Supplemental Content

Support Center